MARKET WIREYahoo Finance • 16h ago
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) TherapeuticsYahoo Finance report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
Why SRPT Stock dropped -3.17% Today — RQD Quant Desk Flash
$18.62 -3.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $18.48
Sarepta Therapeutics Inc. (SRPT) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.97B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SRPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $18.62 (-3.17% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRPT ranks #880 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SRPT compare to SLS and XERS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SRPT?
▼
Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $18.48 (-0.76%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRPT)Realized 20D OHLCV Swing Band: ±10.8%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY SRPT SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)
20D Institutional Volume Accumulation (±10.8% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$16.51+16.1% Next Q
19
Q2 (-2Q)Grade E$19.17-1.5% Next Q
22
Q3 (-1Q)Grade E$18.89-1.4% Next Q
24
CurrentGrade E$18.62-10.3% Hist 90D α
27
Trajectory: E (19) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SRPT Turnaround Squeeze
While SRPT currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.26) and Max Pain ($19.55) forces dealer call-delta covering toward $25.91.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SRPT Stock dropped -3.17% Today — RQD Quant Desk Flash
Sarepta Therapeutics Inc. (SRPT) dropped -3.17% to $18.62, trading at 39% of its 52-week range ($14.68 – $24.68). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 39% of its 52-week range ($14.68 – $24.68) with RSI-14 at 50.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.8% around $18.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 98.6% gross margin and $0 annual free cash flow.
Live SRPT Headlines & Catalysts
MARKET WIRESarepta Therapeutics • 19h ago
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingSarepta Therapeutics report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocktwits • 22h ago
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally NextStocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Sarepta Therapeutics, Inc. News — BMV:SRPTTradingView report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Two Stories Ran On Sarepta Therapeutics. Only One Held UpSimply Wall St report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBusiness Wire • 1d ago
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPTBusiness Wire report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStocktwits • 1d ago
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are SignalingStocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123. Since the thesis was published on August 30th, RARE shares have pulled back as a k
MARKET WIREYahoo • 3d ago
Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In FocusWhy Sarepta Therapeutics Stock Is Back in Focus Sarepta Therapeutics (SRPT) returns to the spotlight as investors look ahead to its November 5 earnings release, with expectations for higher quarterly earnings alongside l
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRPT)
- ✓Walkthrough of SRPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SRPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -15.52%▲ ASCENDING CHANNEL
2026-11-03O $19.23H $19.23L $18.62C $18.62VOL 1.32M
RES: $26.64SUP: $16.81SMA50: $19.26SMA200: $18.70
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SRPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SRPT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SRPT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRPT)
Health Care Rank #880 of 1016
⚔️ SLS vs SRPT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SRPT vs. SLS, XERS, BRVE, TRVI)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Sarepta Therapeutics Inc. (SRPT) ranks #880 by composite RQD confidence (27/100, grade E) and #258 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, SRPT leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SRPT at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SRPT
ACTIVE
Sarepta Therapeutics Inc. | E | 27/100 | — | 96.0% | -35.0% | -3.17% | $1.97B | Benchmark Subject |
| SLS SELLAS Life Sciences Group Inc. | D- | 38/100 | — | — | -21.8% | -4.68% | $1.95B | /sls-vs-srpt → |
| XERS Xeris Biopharma Holdings Inc. | C | 64/100 | — | — | 16.0% | -0.37% | $1.95B | /xers-vs-srpt → |
| BRVE Braveheart Bio Inc. | D | 46/100 | — | — | — | +1.51% | $1.94B | /brve-vs-srpt → |
| TRVI Trevi Therapeutics Inc. | E | 30/100 | — | — | -23.7% | -1.81% | $1.93B | /trvi-vs-srpt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000873303In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported GAAP revenue of $1.86B (+4.3% vs. FY2024 revenue of $1.79B , and +62.8% cumulative change since FY2023) , GAAP net income of -$713.4M, operating cash flow of -$205.5M, and free cash flow of -$307.5M (+10.3% YoY). On the balance sheet, SRPT closed FY2025 with $3.35B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.86B | -$713.4M | -$205.5M | -$307.5M | $3.35B | — |
| FY2024 (FY) | 2024-12-31 | $1.79B | $235.2M | -$205.8M | -$342.7M | $3.96B | — |
| FY2023 (FY) | 2023-12-31 | $1.14B | -$536.0M | -$501.0M | -$501.0M | — | — |
3. SRPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $18.62 (-3.17% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRPT ranks #880 in composite RQD confidence.
How does SRPT compare to SLS and XERS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SRPT?
Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?
SRPT last traded at $18.62 (-3.17% on volume of 1,318,230 shares), positioning the stock -3.32% below its 50-day simple moving average ($19.26) and -0.43% below its 200-day simple moving average ($18.70). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 39.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($16.61 to $20.63).
SRPT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SRPT stock moving today?
Why SRPT Stock dropped -3.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 27/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SRPT — Sarepta Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:57Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, SRPT scores 35/100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -15.14%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the cash engine and insider conviction, indicating that the reported operating losses and negative free cash flow are not yet offset by evidence of insider confidence. The strongest pillar relative to its weight is institutional flow at 11/20, which suggests some institutional positioning, though the source data does not specify its direction or size. The forensic readings (Altman Z 0.2, Piotroski F 4/9) point to balance-sheet fragility. Any upside thesis would rest on the balance-sheet and cash-generation pillars improving, and the source data provides no quantified evidence of that improvement.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1864.3M | $-699.8M | $-713.4M | N/A | $-307.5M | $801.3M | N/A |
| FY 2024 | $1788.0M | $218.1M | $235.2M | N/A | $-342.7M | $1103.0M | N/A |
| FY 2023 | $1144.9M | $-267.8M | $-536.0M | N/A | $-501.0M | N/A | N/A |
Per the SEC financials and market data, FY 2025 shows an operating margin of -37.5% and net margin of -38.3%, with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both consistent with financial stress. Debt/Equity is 0.5 per the RQD rating. Cash declined from $1103.0M (FY 2024) to $801.3M (FY 2025), and free cash flow was negative in all three reported periods.
Recent Catalysts & News Wire Analysis
Per the recent news section, the items include: a Yahoo Finance report on analyst hesitation (headline states that Jim Cramer explained his hesitation over SRPT); a Sarepta release presenting preclinical data on SRP-1003 in DM1 at the 2026 Oligonucleotide Therapeutics Society Annual Meeting; a Stocktwits report on an analyst seeing 34% upside; a TradingView and Yahoo! Finance Canada quote page; and a Simply Wall St piece titled "Two Stories Ran On Sarepta Therapeutics. Only One Held Up." The news feed carries a GREEN light on the Stocktwits item (CATALYST) and YELLOW lights on the others (MARKET WIRE). Risk watch items include the DM1 program remaining at preclinical stage per the Sarepta release and the negative free cash flow trend. The Butterfly supply-chain graph reports no supply chain and no proprietary signals.
Open Questions
- What are the specific revenue drivers behind FY 2025 revenue of $1864.3M, and how does that relate to the swing from positive FY 2024 operating income to a loss in FY 2025?
- What is the debt balance, since the debt field is N/A across all periods while Debt/Equity is cited as 0.5?
- What is the expected path to positive free cash flow given cash fell from $1103.0M to $801.3M?
- What is the commercial status and timeline of the SRP-1003 DM1 program referenced in the news?
- What is the EPS history, since EPS is N/A in every reported period?
SRPT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Sarepta Therapeutics Inc. (SRPT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 16h ago
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics Yahoo Finance report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Sarepta Therapeutics • 19h ago
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting Sarepta Therapeutics report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 22h ago
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Sarepta Therapeutics, Inc. News — BMV:SRPT TradingView report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Two Stories Ran On Sarepta Therapeutics. Only One Held Up Simply Wall St report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Business Wire • 1d ago
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT Business Wire report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stocktwits • 1d ago
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SRPT Bull vs. Bear Conversation Board — What's Your Call at $18.62?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRPT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $16.92 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SRPT (D- • RQD 35/100) a Buy at $19.23?
Welcome to the SRPT (Sarepta Therapeutics Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $16.15 (-16.0%)
Spot @ $19.23 Pump the brakes on SRPT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SRPT, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Sarepta Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $22.88 (+19.0%)
Spot @ $19.23 SRPT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SRPT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.23 (52-wk range $14.68 - $24.68), any beat on forward guidance forces shorts and underweight funds to chase.